Mimoza Bodén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mimoza Bodén has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Björn Frendéus
BioInvent International AB, Lund, Sweden
23 shared publications - David Ermert
BioInvent International AB, Lund, Sweden
23 shared publications - Ingrid Teige
BioInvent International AB, Lund, Sweden
23 shared publications - Jenny Mattsson
BioInvent International AB, Lund, Sweden
23 shared publications - Kirstie L. S. Cleary
University of Southampton 10 Antibody and Vaccine Group, School of Cancer Sciences Southampton, United Kingdom
23 shared publications - Linda Mårtensson
BioInvent International AB, Lund, Sweden
23 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Generated antibodies are TNFR2 specific and act as functional agonists or blockers
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Generated antibodies are TNFR2 specific and act as functional agonists or blockers
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
TNFR2 / TNFR1 ratios, CT26 tumor-bearing mice
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
TNFR2 / TNFR1 ratios, CT26 tumor-bearing mice
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Immune cell infiltration in CT26, MC38 and EMT6 mouse models.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Immune cell infiltration in CT26, MC38 and EMT6 mouse models.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Anti-tumor effect is long-lived and independent of tumor TNFR2 or TNFR1 expression
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Anti-tumor effect is long-lived and independent of tumor TNFR2 or TNFR1 expression
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Both types of α-TNFR2 antibodies have broad anti-tumor effect and synergize with α-PD1
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Both types of α-TNFR2 antibodies have broad anti-tumor effect and synergize with α-PD1
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Ligand-blocking 3F10 and agonist 5A05 bind independently of each other and the inhibiton of anti-tumor effects is dependent on factors beyond FcγR competition
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Ligand-blocking 3F10 and agonist 5A05 bind independently of each other and the inhibiton of anti-tumor effects is dependent on factors beyond FcγR competition
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Characterization of transcriptionally distinct cell populations following antibody treatments.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Characterization of transcriptionally distinct cell populations following antibody treatments.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Flow cytometry histograms for myeloid sub-population identification
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Flow cytometry histograms for myeloid sub-population identification
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
RAG-/- mouse reconstitution with hTNFR2+/+ lymphocytes.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
RAG-/- mouse reconstitution with hTNFR2+/+ lymphocytes.